Investor Presentaiton
KEMENTERIAN
KESEHATAN
REPUBLIK
INDONESIA
Vaccine name
(Name of
manufacturer)
Total
number of
doses given
Vaccine safety monitoring (as of 13 July 2021)
Cumulative
number of AEFI
reported
Number of
AEFI reported
for 100,000
doses
Serious AEFI (cumulative)
Total number of
serious AEFI
reported
Number of
Serious AEFI
reported per
100,000 doses
Number of
serious AEFI
investigated
Causality
assessment
completed on
serious cases
Proportion of
causality
assessment
conducted
AstraZeneca-
7 350 987
2 888
39.29
37
0.50
37
32
86.49
SKBio
Sinopharm
(BIBP)
266 073
1
0.38
1
0.38
1
1
100.00
Sinovac
40 862 871
10 108
24.74
254
0.62
254
241
94.88
Causality assessment:
•
Total 28 cases were classified as vaccine product related assessment, 1 was related to Astrazeneca, 27
were related to Sinovac.
•
7 anaphylaxis cases were related to Sinovac, no death.View entire presentation